Want to see IRWD full AI Analyst Report?
IRWD Stock Chart & Stats
$3.71
$0.20(5.39%)
At close: 4:00 PM EDT
$3.71
$0.20(5.39%)
Day’s Range― - ―
52-Week Range$1.01 - $5.78
Previous Close$3.96
Volume1.93M
Average Volume (3M)2.34M
Market Cap
$712.18M
Enterprise Value$1.02K
Total Cash (Recent Filing)$79.13M
Total Debt (Recent Filing)$396.87M
Price to Earnings (P/E)5.4
Beta1.01
Next Earnings
Oct 29, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding165,239,940
10 Day Avg. Volume1,576,550
30 Day Avg. Volume2,343,106
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.09
Price to Sales (P/S)1.85
P/FCF Ratio4.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.19
Revenue Forecast (FY)$460.02M
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt And Financial UncertaintyThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory ChallengesThe FDA requires another confirmatory Phase 3 trial for Apraglutide to validate its efficacy and match previous exposure levels.
Ironwood Pharma News
IRWD FAQ
What was Ironwood Pharmaceuticals’s price range in the past 12 months?
Ironwood Pharmaceuticals lowest stock price was $1.01 and its highest was $5.78 in the past 12 months.
What is Ironwood Pharmaceuticals’s market cap?
Ironwood Pharmaceuticals’s market cap is $712.18M.
When is Ironwood Pharmaceuticals’s upcoming earnings report date?
Ironwood Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 73 days.
How were Ironwood Pharmaceuticals’s earnings last quarter?
Ironwood Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by -$0.01.
Is Ironwood Pharmaceuticals overvalued?
According to Wall Street analysts Ironwood Pharmaceuticals’s price is currently Overvalued.
Does Ironwood Pharmaceuticals pay dividends?
Ironwood Pharmaceuticals does not currently pay dividends.
What is Ironwood Pharmaceuticals’s EPS estimate?
Ironwood Pharmaceuticals’s EPS estimate is 0.33.
How many shares outstanding does Ironwood Pharmaceuticals have?
Ironwood Pharmaceuticals has 165,239,940 shares outstanding.
What happened to Ironwood Pharmaceuticals’s price movement after its last earnings report?
Ironwood Pharmaceuticals reported an EPS of $0.31 in its last earnings report, missing expectations of $0.32. Following the earnings report the stock price went up 2.651%.
Which hedge fund is a major shareholder of Ironwood Pharmaceuticals?
Currently, no hedge funds are holding shares in IRWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ironwood Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
IRWD Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 42.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
352.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.86%
Trailing 12-Months
Company Description
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
IRWD Company Deck
IRWD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive commercial and financial story driven by LINZESS: strong Q2 sales, significant YTD growth, an upward revision to full-year guidance, a pediatric label expansion, and robust quarterly profitability. Clinical progress on apraglutide (initiation of STARS-2 and supportive STARS/STARS-Extend data) and actions to strengthen the balance sheet (repayment of convertible notes and target to reduce gross leverage) are additional positives. Offsetting risks include dependence on LINZESS for revenue, early-stage enrollment uncertainty for STARS-2, remediation required after a prior dosing kit error, anticipated higher R&D/SG&A spend in H2, and a modest cash balance that increases reliance on operating cash flow and receivables.View all IRWD earnings summariesIRWD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Evotec AG
―
Collegium Pharmaceutical
―
Ownership Overview
3.82% Insiders
15.68% Mutual Funds
20.71% Other Institutional Investors
36.85% Public Companies and
Individual Investors